trending Market Intelligence /marketintelligence/en/news-insights/trending/uiSvJ26_t4Us_G4gjPcFow2 content esgSubNav
In This List

Catalent to invest $200M in biologics manufacturing expansion

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Catalent to invest $200M in biologics manufacturing expansion

Catalent Inc. started a $200 million capital investment program to expand its biologics manufacturing capacity and capabilities.

Under the three-year investment program, Catalent will increase the mammalian cell culture capacity of its Madison, Wis.-based facility by building two new suites. The company expects to complete the construction by mid-2021, resulting in a more than doubled commercial biomanufacturing capacity.

The company will also extend its Bloomington, Ind.-based site by 79,000 square feet to boost the facility's fill and finish capacity. In December 2018, Catalent invested $14 million to expand the biologics packaging capabilities of the Bloomington facility.

Somerset, N.J.-based Catalent provides advanced delivery technologies and development for drugs, biologics and consumer health products.